

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Heike Winter Sederoff, et al.  
Appl. No. : 10/576,757 (national stage filing of **PCT/US04/034996**)  
Filed : 10/20/2004  
Title : Synthetic Peptides that Cause F-Actin Bundling and  
Block Actin Depolymerization  
Grp./Art Unit : Unassigned  
Examiner : Unassigned  
Docket No. : JIB-1571US

CERTIFICATE OF MAILING			
I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being submitted electronically to the U.S. Patent and Trademark Office on the date and time shown below.			
Name (Type/Print)	Michelle S. Chew		
Signature	/Michelle S. Chew/	Date	06/16/2008 7:05PM EDT

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE  
MAILED 05/15/2008**

Dear Sir:

This is in reply to a Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed 15 May 2008. The Office noted that the Sequence Listing supplied by the 03/05/2007 response did not comply with the requirements of 37 CFR 1.822 and/or 1.823. Applicants were requested to supply a

substitute copy of the “Sequence Listing” in computer readable form and a statement that the content of the sequence listing information is identical to the paper form. Applicants believe this Response is timely filed by the 1-month deadline to respond.

In response, submitted herewith is a copy of the substitute sequence listing in computer readable form, as a .txt file, entitled, **JIB1571\_import\_ST25.txt**. Applicants certify that the sequence listing information recorded in computer readable form herein submitted is identical to the substitute paper copy of the sequence listing, also submitted. No new matter is involved. Applicants respectfully request entry of the Sequence listing into the present application.

Applicants reviewed the marked up copy of the Raw Sequence Listing as provided by the Office and also spoke with Ms. Anne-Marie Coorigan, one of the Sequence Reviewers at the Office to determine what the acceptable responses would be and how to correct the Sequence Listing to comply with the requirements of 37 CFR 1.822 and/or 1.823.

The original Reviewer noted that the many of the sequences contained incomplete feature listings shown for example here below:

```
<220>
<221> peptide
<222> (1) .. (15)
```

Applicants have removed these named features for all the sequences and have placed this information in the appropriate identified section of <223> as indicated by the Office as the appropriate section for such information. Applicants also have removed the organism that each peptide is derived from and instead placed this information in the description in <223> which is the appropriate section for this information. Since each peptide is a synthetic peptide, each sequence was labeled as Artificial at <213> which according to the Office would be more appropriate and place these sequences in compliance. The descriptions placed in the <223> for

each sequence is description for each peptide found at pages 3-4 and in Tables 1, 2 and 3 in the specification.

It was also noted that for SED ID NOS: 5 and 6, that two different species cannot be indicated at <213>. Applicants have placed this information as a feature noted in <223> for SEQ ID NOS: 5 and 6. Applicants also correct the description for SITE (6) in SEQ ID NO: 13, to recite that the Tryptophan residue was replaced with "Alanine" not "Alanines". This change is supported by the fact that SEQ ID NO:13 has only a single Alanine at position 6 and no Alanines at positions 5 or 7.

Applicants have also included the assigned US Patent Application Serial No. for the present application in the Sequence Listing.

Applicants believe that these changes to the Sequence Listing are not new matter, but rather are required to place the Sequence Listing into compliance. Although no fee is believed necessary for entry of this Amendment, the PTO is authorized to charge any necessary and additional fees that may be due to Deposit Account No. 12-0690. In furtherance of prosecution, the Examiner is invited to call the undersigned to discuss the application and its claims.

Respectfully submitted,

Dated 06/16/2008

BY /Michelle S. Chew/  
Michelle S. Chew  
Reg. No. 50,456  
(510) 495-2456

Lawrence Berkeley National Laboratory  
One Cyclotron Road, Mail Stop 90B  
Berkeley, California 94720  
Telephone (510) 486-7058  
Facsimile (510) 486-7896